Teleflex Reaffirms FY22 Outlook

While providing an update on its business, 2023-2025 business growth strategy and financial goals ahead of its 2022 Analyst & Investor Day in New York City later on Friday, medical devices maker Teleflex, Inc. (TFX) reaffirmed its earnings and revenue growth guidance for full-year 2022.

For fiscal 2022, the company continues to project earnings from continuing operations in a range of $8.85 to $9.45 per share and adjusted earnings from continuing operations in a range of $13.70 to $14.30 per share on revenue growth of 2.3 to 3.8 percent, with constant currency revenue growth of 4.0 to 5.5 percent.

On average, 11 analysts polled by Thomson Reuters expect the company to report earnings of $13.96 per share on revenue growth of 3.10 percent to $2.90 billion for the year. Analysts' estimates typically exclude special items.

The company also said it expects 6 to 7 percent compounded annual constant currency revenue growth rate from year-end 2022 through year-end 2025.

The company noted that it intends to continue to pursue business optimization opportunities that drive margin improvement and target acquisition candidates that complement its existing business, have differentiated products, and can strengthen its financial profile.

It expects its 3-year growth strategy to accelerate the Company's revenue growth, deliver gross and operating margin expansion and generate strong free cash flow.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Primal Pet Foods is recalling a single lot of Raw Frozen Primal Patties for Dogs Beef Formula due to potential contamination with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves lot #W10068709 of 6-pound Raw Frozen Primal Patties with best by date of 05/22/23. The Raw Frozen Primal Patties are sold in flexible packaging in the freezer at select pet stores. The U.S. Food and Drug Administration has authorized state-licensed pharmacists to prescribe COVID-19 pill Paxlovid (nirmatrelvir and ritonavir) by drug major Pfizer Inc. to eligible patients, with certain limitations. The agency has revised the Emergency Use Authorization or EUA for Paxlovid for the authorization, which could improve access for some patients at high risk for severe covid-19. Retail major Walmart's popular InHome direct-to-fridge delivery service is now available as an optional add-on within its membership plan Walmart+. Walmart also launched InHome service, which delivers groceries straight to one's fridge, in several new markets including Miami, Tampa, Orlando, Dallas, Austin, San Jose and San Francisco.
Follow RTT